Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861457 | 0.84 | CYP1A2 (1.00) | CYP1A2CYP2D6ALDH1A1NPSR1CHRM2 | |
| SCHEMBL1044020 | 0.83 | CYP1A2 (0.75) | CYP1A2CYP2D6ALDH1A1NPSR1CHRM2 | |
| SCHEMBL1043672 | 0.83 | SLC2A4 (0.51) | CYP1A2CYP2D6ALDH1A1NPSR1HTT | |
| Hydrochloric Acid SCHEMBL6121350 | 0.82 | CYP1A2 (0.95) | CYP1A2CYP2D6ALDH1A1NPSR1CHRM2 | |
| SCHEMBL10492340 | 0.81 | CYP11B1 (0.46) | CYP1A2CYP2D6 | |
| SCHEMBL6293446 | 0.81 | CHRNA7 (0.53) | CYP1A2CYP2D6TDP1 | |
| SCHEMBL3318487 | 0.81 | LTA4H (0.57) | CYP1A2CYP2D6ALDH1A1LTA4H | |
| SCHEMBL10054984 | 0.80 | CYP1A2 (0.91) | CYP1A2CYP2D6ALDH1A1NPSR1CHRM2 | |
| SCHEMBL1042402 | 0.78 | CYP1A2 (0.88) | CYP1A2CYP2D6ALDH1A1NPSR1CHRM2 | |
| SCHEMBL22304865 | 0.78 | CYP1A2 (0.88) | CYP1A2CYP2D6ALDH1A1NPSR1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725528-B1 | SULPHONYLPYRROLES AS HDAC INHIBITORS | 4SC AG (DE) | 2013-05-29 | — | — | EP | claimed |
| WO-2019043176-A2 | HDAC INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | 4SC AG (DE) | 2019-03-07 | — | — | WO | disclosed |
| US-8969401-B2 | Sulfonylpyrroles | 4SC AG (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-1725528-B1 | SULPHONYLPYRROLES AS HDAC INHIBITORS | 4SC AG (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20130079347-A1 | NOVEL SULFONYLPYRROLES | ALTANA PHARMA AG (DE) | 2013-03-28 | — | — | US | disclosed |
| US-8399505-B2 | Sulfonylpyrroles | 4SC AG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8232297-B2 | Sulphonylpyrroles as inhibitors of HDACs novel sulphonylpyrroles | 4SC AG (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8188138-B2 | Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors | 4SC AG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8067615-B2 | Sulphonylpyrroles | 4SC AG (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20110166140-A1 | NOVEL SULPHONYLPYRROLES | MAIER THOMAS | 2011-07-07 | — | — | US | disclosed |
| EP-1928872-A1 | NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES | Nycomed GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-27 | — | — | US | disclosed |
| US-20070184979-A1 | Novel sulfonylpyrroles | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | disclosed |
| WO-2007039404-A1 | NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039403-A1 | SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1725528-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | disclosed |
| EP-1641465-A2 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | Theravance, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005087724-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005025555-A2 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070184979-A1 | Novel sulfonylpyrroles | HDAC1, HDAC4, HDAC3 | CYP1A2 2058/4885CYP2D6 1684/4885ALDH1A1 389/4885 |
| US-20110166140-A1 | NOVEL SULPHONYLPYRROLES | HDAC1, HDAC3, HDAC2 | CYP1A2 1432/4885CYP2D6 1880/4885ALDH1A1 897/4885 |
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB3, ADRB1 | CYP1A2 67/4885CYP2D6 296/4885ALDH1A1 614/4885 |
| US-20130079347-A1 | NOVEL SULFONYLPYRROLES | HDAC3, HDAC1, HDAC2 | CYP1A2 2626/4885CYP2D6 2999/4885ALDH1A1 1504/4885 |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | CYP1A2 65/4885CYP2D6 282/4885ALDH1A1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.